Novolizer Formoterol Meda (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Novolizer Formoterol Meda, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry‑powder inhalation formulation for inhalation use. It provides bronchodilation for patients with chronic obstructive pulmonary disease and asthma.

GNH USA supplies Novolizer Formoterol Meda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novolizer Formoterol Meda is a LABA that acts on the bronchial smooth‑muscle pathway to improve airflow. - Asthma: improves control of symptoms and reduces the frequency of bronchospasm episodes. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases the need for rescue medication. - Exercise‑induced bronchoconstriction: provides prophylactic bronchodilation for patients undertaking physical activity.

Formoterol may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Tremor: mild, transient shaking of the hands. - Headache: dull or throbbing pain, often short‑lived. - Throat irritation: discomfort or dryness in the throat after inhalation. - Cough: brief episodes triggered by the powder inhaler. - Palpitations: sensation of a rapid or irregular heartbeat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airway obstruction. - Cardiovascular events: arrhythmia, angina, or myocardial ischaemia. - Hypokalaemia: low blood potassium levels, potentially causing muscle weakness. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Novolizer Formoterol Meda, clinicians should consider several safety aspects. - Assess respiratory status: confirm diagnosis of asthma or COPD before initiation. - Monitor cardiac function: patients with known heart disease should be observed for arrhythmias. - Avoid overuse: limit use to the prescribed frequency to prevent tolerance. - Review concomitant medications: check for other β2‑agonists or monoamine oxidase inhibitors. - Educate on inhaler technique: ensure patients can correctly load and inhale the powder. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Formoterol can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: may antagonise bronchodilatory effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Other long‑acting β2‑agonists: additive bronchodilation may raise risk of tachycardia. - Diuretics that cause hypokalaemia: may potentiate cardiac effects of β2‑agonism. - Theophylline: concurrent use can enhance stimulant effects on the heart.